

R W Paterson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2094321/publications.pdf>

Version: 2024-02-01

27
papers

1,959
citations

430442

18
h-index

500791

28
g-index

30
all docs

30
docs citations

30
times ranked

3531
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
2	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 3.	4.4	236
3	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1240-1247.	0.9	196
4	Increased CSF neurogranin concentration is specific to Alzheimer disease. <i>Neurology</i> , 2016, 86, 829-835.	1.5	170
5	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. <i>Molecular Neurodegeneration</i> , 2015, 10, 64.	4.4	121
6	Biomarkers in dementia: clinical utility and new directions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1426-1434.	0.9	119
7	Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 625-630.	0.9	106
8	Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 708-713.	0.9	97
9	Diagnosis and treatment of rapidly progressive dementias. <i>Neurology: Clinical Practice</i> , 2012, 2, 187-200.	0.8	68
10	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2021, 290, 583-601.	2.7	54
11	A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology. <i>Translational Psychiatry</i> , 2016, 6, e952-e952.	2.4	46
12	Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. <i>Translational Psychiatry</i> , 2014, 4, e419-e419.	2.4	39
13	Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. <i>Journal of Neurology</i> , 2015, 262, 2722-2730.	1.8	39
14	Identification of an important potential confound in CSF AD studies: aliquot volume. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 2311-7.	1.4	37
15	SILK studies " capturing the turnover of proteins linked to neurodegenerative diseases. <i>Nature Reviews Neurology</i> , 2019, 15, 419-427.	4.9	37
16	Amyloid processing in COVID-19-associated neurological syndromes. <i>Journal of Neurochemistry</i> , 2022, 161, 146-157.	2.1	35
17	CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 162-171.	1.7	30
18	A blood miRNA signature associates with sporadic Creutzfeldt-Jakob disease diagnosis. <i>Nature Communications</i> , 2020, 11, 3960.	5.8	20

#	ARTICLE	IF	CITATIONS
19	Recurrent Stereotyped Episodes in Cerebral Amyloid Angiopathy: Response to Migraine Prophylaxis in Two Patients. <i>Cerebrovascular Diseases Extra</i> , 2013, 3, 81-84.	0.5	12
20	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease. <i>Clinical Mass Spectrometry</i> , 2019, 14, 74-82.	1.9	9
21	Mass spectrometry analysis of tau and amyloid-beta in iPSC-derived models of Alzheimer's disease and dementia. <i>Journal of Neurochemistry</i> , 2021, 159, 305-317.	2.1	8
22	Do cerebrospinal fluid transfer methods affect measured amyloid β_{242} , total tau, and phosphorylated tau in clinical practice?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 380-384.	1.2	5
23	Subacute peripheral and optic neuropathy syndrome with no evidence of a toxic or nutritional cause. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1389-1393.	0.6	4
24	Biomarker Modelling of Early Molecular Changes in Alzheimer's Disease. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 213-227.	1.6	4
25	CSF biomarkers for dementia. <i>Practical Neurology</i> , 2022, 22, 285-294.	0.5	3
26	Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy. <i>Clinical Neurology and Neurosurgery</i> , 2016, 144, 64-66.	0.6	1
27	Career mentorship for young neurologists in Europe. <i>Neurology</i> , 2012, 79, 381-383.	1.5	0